Prasugrel Monotherapy Reduced dose in Acute and Chronic Coronary Syndrome Patients after Percutaneous Coronary Intervention

Conditions

Acute coronary syndrome and chronic coronary syndrome

Brief summary

Net Adverse Clinical Events (NACE), a composite of all-cause mortality, myocardial infarction, definite stent thrombosis, ischemic stroke, major bleeding or clinically relevant non-major bleeding defined as BARC type 2, 3 or 5

Detailed description

Treatment satisfaction, based on the Treatment Satisfaction Questionnaire for Medication II (TSQM-II), Treatment adherence, based on the Morisky Medication Adherence Scale (MMAS-8), Each individual component of the primary endpoint, Cardiovascular mortality, Non-cardiovascular mortality, Any need for revascularization, Major or clinically relevant non-major bleeding defined as BARC type 2, 3 or 5, Minor or clinically relevant non-major bleeding defined as BARC type 2 at 1, 6 and 12 month(s), Any periprocedural complications, On-treatment platelet reactivity at week 2 in the first 40 patients, Non-adherence to antiplatelet regimen

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGEfient 5 mg film-coated tablets.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Net Adverse Clinical Events (NACE), a composite of all-cause mortality, myocardial infarction, definite stent thrombosis, ischemic stroke, major bleeding or clinically relevant non-major bleeding defined as BARC type 2, 3 or 5	—

Secondary

Measure	Time frame
Treatment satisfaction, based on the Treatment Satisfaction Questionnaire for Medication II (TSQM-II), Treatment adherence, based on the Morisky Medication Adherence Scale (MMAS-8), Each individual component of the primary endpoint, Cardiovascular mortality, Non-cardiovascular mortality, Any need for revascularization, Major or clinically relevant non-major bleeding defined as BARC type 2, 3 or 5, Minor or clinically relevant non-major bleeding defined as BARC type 2 at 1, 6 and 12 month(s), Any periprocedural complications, On-treatment platelet reactivity at week 2 in the first 40 patients, Non-adherence to antiplatelet regimen	—

Measure

Time frame

Treatment satisfaction, based on the Treatment Satisfaction Questionnaire for Medication II (TSQM-II), Treatment adherence, based on the Morisky Medication Adherence Scale (MMAS-8), Each individual component of the primary endpoint, Cardiovascular mortality, Non-cardiovascular mortality, Any need for revascularization, Major or clinically relevant non-major bleeding defined as BARC type 2, 3 or 5, Minor or clinically relevant non-major bleeding defined as BARC type 2 at 1, 6 and 12 month(s), Any periprocedural complications, On-treatment platelet reactivity at week 2 in the first 40 patients, Non-adherence to antiplatelet regimen

—

Countries

Netherlands

Outcome results

None listed